SOX17 Antagonizes the WNT Signaling Pathway and is Epigenetically Inactivated in Clear-Cell Renal Cell Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Chen L, Kim PH, et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Assoc J. 2013;7(11–12):E687–E691. doi:10.5489/cuaj.1447
   PubMed Web of Science ®Google Scholar
• De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD, Dryer D. Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986–2007. Cancer Causes Control. 2014;25(10):1271–1281. doi:10.1007/s10552-014-0427-x
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–428. doi:10.1038/nrg816
   PubMed Web of Science ®Google Scholar
• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6–21. doi:10.1101/gad.947102
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–2054. doi:10.1056/NEJMra023075
   PubMed Web of Science ®Google Scholar
• Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006;47(4):365–375. doi:10.1007/BF03194647
   PubMed Web of Science ®Google Scholar
• Majchrzak-Celinska A, Paluszczak J, Szalata M, et al. The methylation of a panel of genes differentiates low-grade from high-grade gliomas. Tumour Biol. 2015;36(5):3831–3841. doi:10.1007/s13277-014-3025-3
   PubMedGoogle Scholar
• Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999;27(6):1409–1420. doi:10.1093/nar/27.6.1409
   PubMed Web of Science ®Google Scholar
• Fu DY, Wang ZM, Wang BL, Shen ZZ, Huang W, Shao ZM. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat. 2010;119(3):601–612.
   PubMed Web of Science ®Google Scholar
• Kim I, Saunders TL, Morrison SJ. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell. 2007;130(3):470–483. doi:10.1016/j.cell.2007.06.011
   PubMed Web of Science ®Google Scholar
• Sinner D, Kordich JJ, Spence JR, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007;27(22):7802–7815. doi:10.1128/MCB.02179-06
   PubMed Web of Science ®Google Scholar
• Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2013;59(1):270–279.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010;5(8):743–749. doi:10.4161/epi.5.8.13104
   PubMed Web of Science ®Google Scholar
• Balgkouranidou I, Karayiannakis A, Matthaios D, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med. 2013;51(7). doi:10.1515/cclm-2012-0320.
   PubMed Web of Science ®Google Scholar
• Li JY, Han C, Zheng LL, Guo MZ. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma. Chin Med J (Engl). 2012;125(19):3526–3531.
   PubMed Web of Science ®Google Scholar
• Stovall DB, Wan M, Miller LD, et al. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183(5):1645–1653. doi:10.1016/j.ajpath.2013.07.025
   PubMed Web of Science ®Google Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. doi:10.1146/annurev.cellbio.20.010403.113126
   PubMed Web of Science ®Google Scholar
• Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–398. doi:10.1038/nrc2389
   PubMed Web of Science ®Google Scholar
• Batra H, Antony VB. The pleural mesothelium in development and disease. Front Physiol. 2014;5:284. doi:10.3389/fphys.2014.00284
   PubMed Web of Science ®Google Scholar
• Bodnar L, Stec R, Cierniak S, et al. Role of WNT/beta-catenin pathway as potential prognostic and predictive factors in renal cell cancer patients treated with everolimus in the second and subsequent lines. Clin Genitourin Cancer. 2018;16(4):257–265. doi:10.1016/j.clgc.2018.01.008
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yamamura S, Hirata H, et al. Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer. 2011;128(3):541–550. doi:10.1002/ijc.25357
   PubMed Web of Science ®Google Scholar
• Wang L, Fan Y, Zhang L, et al. Classic SRY‐box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma. FASEB J. 2018;33(1):254–263. doi:10.1096/fj.201701453RR
   PubMed Web of Science ®Google Scholar
• Ueno K, Hirata H, Majid S, et al. Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog. 2011;50(6):449–457. doi:10.1002/mc.20729
   PubMed Web of Science ®Google Scholar
• Taneja K, Williamson SR. Updates in pathologic staging and histologic grading of renal cell carcinoma. Surg Pathol Clin. 2018;11(4):797–812. doi:10.1016/j.path.2018.07.004
   PubMedGoogle Scholar
• Zhang Q, Ying J, Zhang K, et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett. 2007;249(2):220–226. doi:10.1016/j.canlet.2006.08.019
   PubMed Web of Science ®Google Scholar
• Wang L, Cui Y, Sheng J, et al. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification. Oncotarget. 2017;8(13):21861–21870. doi:10.18632/oncotarget.15668
   PubMedGoogle Scholar
• Peters I, Eggers H, Atschekzei F, et al. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. Bju Int. 2012;110(2b):E144–E152. doi:10.1111/j.1464-410X.2011.10862.x
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222
   PubMed Web of Science ®Google Scholar
• Fu D, Ren C, Tan H, et al. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine. 2015;94(11).
   Web of Science ®Google Scholar
• Wang C, Wang Y, Hong T, et al. Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma. Cell Death Differ. 2020.
   Web of Science ®Google Scholar
• Morris MR, Ricketts C, Gentle D, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29(14):2104–2117. doi:10.1038/onc.2009.493
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, Hill VK, Linehan WM. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One. 2014;9(1):e85621. doi:10.1371/journal.pone.0085621
   PubMed Web of Science ®Google Scholar
• Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res. 2006;12(23):6989–6997. doi:10.1158/1078-0432.CCR-06-1194
   PubMed Web of Science ®Google Scholar
• Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer. 2011;128(8):1793–1803. doi:10.1002/ijc.25507
   PubMed Web of Science ®Google Scholar
• Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64(15):5511–5517. doi:10.1158/0008-5472.CAN-04-0799
   PubMed Web of Science ®Google Scholar
• Hauser S, Zahalka T, Fechner G, Muller SC, Ellinger J. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res. 2013;33(10):4651–4656.
   PubMed Web of Science ®Google Scholar
• Battagli C, Uzzo RG, Dulaimi E, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003;63(24):8695–8699.
   PubMed Web of Science ®Google Scholar